Regeneron Pharmaceuticals, Inc. (REGN) falls 11.9% on trial miss
May 18, 20266 min read
Key Takeaway
Regeneron Pharmaceuticals, Inc. (REGN) falls 11.9% in after-hours trading after its late-stage melanoma trial for fianlimab failed to meet the primary endpoint. The setback, combined with same-day analyst downgrades and lingering Eylea erosion concerns, has forced investors to reassess the company’s near-term growth outlook. Despite strong profitability and solid recent earnings, the stock is being repriced lower because the pipeline disappointment weakens a key part of the bull case.
Regeneron Pharmaceuticals, Inc. (REGN) falls sharply in after-hours trading, dropping to $615 from a prior regular-session close of $698.25, a decline of 11.92%. The most direct reason is a fresh clinical setback: Regeneron said its late-stage melanoma study for fianlimab failed to meet its primary endpoint, a result that hit both sentiment and the company’s oncology growth narrative.
Key Takeaways
REGN fell 11.92% in extended-hours trading, with shares printing at $615 versus a prior close of $698.25.
The clearest catalyst is a Phase 3 melanoma trial failure for fianlimab, which missed its primary goal against a market that wanted a cleaner oncology win.
The selloff was reinforced by analyst cuts on May 18, including a Citigroup downgrade to Neutral and a Leerink move to Market Perform with a $641 target tied to the LAG-3 failure and Eylea erosion risk.
Financially, Regeneron still looks profitable, with trailing EPS of 40.99 and a P/E of 17.03, and it posted Q1 2026 adjusted EPS of $9.47 on $3.61B in revenue.
For investors, the message is simple: strong core earnings did not offset a new pipeline disappointment and renewed concern around two major value drivers, oncology upside and the Eylea franchise.
Why Regeneron Pharmaceuticals, Inc. Stock Falls After Hours Today
The main trigger is concrete. On May 18, headlines reported that Regeneron’s late-stage trial of fianlimab in melanoma missed its goal. One report said the skin cancer drug failed to beat Merck’s Keytruda, which matters because Keytruda remains the benchmark in this market.
That kind of miss tends to hit biotech stocks hard for a simple reason. A Phase 3 failure does more than delay revenue. It weakens the case that a company can turn a promising mechanism into a durable commercial product. In Regeneron’s case, fianlimab was part of the broader effort to deepen its oncology portfolio beyond existing assets such as Libtayo.
The market also got a second negative push from Wall Street. Citigroup downgraded REGN to Neutral from Buy on May 18. Leerink also cut the stock to Market Perform and set a $641 target, explicitly citing the LAG-3 failure and Eylea erosion risk. When bad trial data and same-day downgrades arrive together, the stock often takes the fast route lower.
The Melanoma Trial Miss Hurts Regeneron’s Oncology Growth Story
The trial result matters because oncology is one of the areas where Regeneron has tried to build another leg of growth. The company already has a strong base business, but large biotech valuations often depend on more than current sales. They also depend on whether the pipeline can keep replacing aging products and expanding into new markets.
Here, the disappointment lands in a sensitive spot. Regeneron has meaningful exposure to a few major franchises, including Eylea and its collaboration economics around Dupixent. A failed late-stage melanoma program does not break the company, but it does remove part of the upside case investors were willing to pay for.
There is also a competitive angle. Missing against Keytruda is not a minor stumble. It tells investors that taking share in frontline melanoma remains difficult, even with a novel combination. In plain English, the science did not turn into a stronger commercial weapon, and the stock is being repriced for that.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Regeneron Financials Still Show Strength, but the Market Is Repricing Risk
Importantly, this selloff is not happening because Regeneron suddenly became unprofitable. The company remains a large, profitable biotech with a $71.94B market cap, trailing EPS of 40.99, and a P/E of 17.03. That valuation is not extreme by growth-biotech standards, especially for a company with established products and a low beta of 0.296.
Recent earnings were also solid. In Q1 2026, Regeneron reported adjusted EPS of $9.47, up 15% year over year, on revenue of $3.61B, up 19%. It has beaten EPS estimates in 7 of the last 8 quarters, including a 3.4% beat in the most recent report. Those are not the numbers of a business in operating trouble.
However, stocks do not trade on backward-looking strength alone. They trade on what that strength is worth after new information changes the future path. Today’s trial failure does exactly that. It trims confidence in pipeline execution, and that can compress the multiple even when the income statement still looks healthy.
Eylea HD Delays Add to Pressure on the REGN Investment Case
The after-hours drop also lands on top of an older concern that never fully left the story. In its April 29 Q1 2026 update, Regeneron reported strong results but also flagged FDA delays tied to the Eylea HD prefilled syringe. Specifically, the FDA did not act by the April 2026 PDUFA date for a second contract manufacturer application, while Regeneron resubmitted an application related to filling at Catalent in Indiana.
That matters because Eylea and Eylea HD remain central to Regeneron’s ophthalmology franchise. Q1 Eylea HD sales reached $468M, up 52% year over year, which shows real demand. Still, regulatory and manufacturing friction around a key franchise can cap enthusiasm, especially when analysts are already talking about erosion risk.
This is why the selloff feels larger than one trial headline. The melanoma miss hit the pipeline. The Eylea HD issue was already pressuring confidence in execution. Together, they create a cleaner bear case than the market had a week ago.
The first takeaway is that REGN still has real business strength. Consensus analyst ratings remain skewed positive, with 34 Buy ratings and 14 Hold ratings, and the broader target consensus stands at $853.47. Even after the latest cuts, that backdrop shows the Street still sees value in the core franchise.
Still, the stock’s direction in the near term will depend less on trailing earnings and more on whether investors believe Regeneron can replace lost pipeline optimism with other programs or stronger commercial execution. The market is ruthless with large biotech names when a premium pipeline story cracks. A stock can be a good company and still take a hard reset. REGN is dealing with that reset now.
For disciplined investors, the practical read is to separate the business from the trade. The business remains profitable and established. The trade, however, just absorbed a late-stage trial failure and fresh downgrades, which usually keeps pressure on sentiment until a stronger counterweight emerges.
Regeneron’s after-hours drop looks tied first to the failed Phase 3 melanoma study for fianlimab, with analyst downgrades and existing Eylea concerns adding force to the move. Because this is an extended-hours reaction, the next regular session will show whether the market treats this as a one-day shock or the start of a deeper repricing.
REGN stock is down because Regeneron reported that its late-stage melanoma trial for fianlimab missed its primary endpoint. The decline was also worsened by analyst downgrades and renewed concern about Eylea franchise erosion.
+Should I buy REGN stock now?
The article suggests caution in the near term because the stock is being repriced after a pipeline setback. Regeneron still has strong earnings and profitability, but investors may want to wait for the market to digest the trial miss and analyst revisions.
+Did Regeneron lose money in the latest quarter?
No. Regeneron remains profitable and recently reported adjusted EPS of $9.47 on $3.61 billion in revenue. The stock drop is about future growth expectations, not current profitability.
+What does the fianlimab trial failure mean for Regeneron?
It weakens Regeneron’s oncology growth story and removes a potential upside driver for the stock. The miss does not break the business, but it lowers confidence in the pipeline and can pressure the valuation.
Want the full picture on REGN?
Read the analyst-grade research report — charts, grades, and price targets.
